| Identification | Back Directory | [Name]
FX-909 | [CAS]
2924573-90-8 | [Synonyms]
FX-909
3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methylsulfonyl)benzonitrile | [Molecular Formula]
C17H10F2N2O3S | [MOL File]
2924573-90-8.mol | [Molecular Weight]
360.34 |
| Chemical Properties | Back Directory | [Boiling point ]
584.3±50.0 °C(predicted) | [density ]
1.55±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [solubility ]
Acetonitrile: Slightly soluble: 0.1-1 mg/ml
DMSO: Sparingly soluble: 1-10 mg/ml
Water: Slightly soluble: 0.1-1 mg/ml | [form ]
Solid | [pka]
-0.69±0.70(predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
FX-909 is a covalent peroxisome proliferator-activated receptor gamma (PPARG) inverse agonist. FX-909 can be used for the research of cancer[1]. | [in vivo]
FX-909 (0.03-1 mg/kg; BID for 21 days) shows anticancer effects in UMUC9 UC xenograft mouse model[1]. | [IC 50]
PPARγ | [References]
[1] Mertz J A, et al. Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG). Cancer Research, 2023, 83(7_Supplement): 2802-2802. |
|
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0510-83588313-811 18800520310 |
| Website: |
www.jiehuapharma.com/ |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|